network member

Washington, D.C.

About Network Member

Enrollment Closed

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Columbia University Irving Medical Center
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
John Theurer Cancer Center at Hackensack Meridian Health
Moores Cancer Center at UC San Diego
Penn Medicine Abramson Cancer Center
The Ohio State University
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Weill Cornell Medicine
Winship Cancer Institute of Emory University
Yale Cancer Center
Enrollment Closed

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
University of Alabama at Birmingham Comprehensive Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Enrollment Closed

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma
Cancer areas:Melanoma
Columbia University Irving Medical Center
Georgetown Lombardi Comprehensive Cancer Center
MD Anderson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
UC San Francisco